Heptares Orphan Disease Programme Awarded Grant from the UK Biomedical Catalyst

News provided by

Nov 20, 2014, 10:16 ET

LONDON and BOSTON, November 20, 2014 /PRNewswire/ --

Project to develop first-in-class selective and orally available GLP-1 receptor antagonist for treating severe hypoglycaemia (low blood glucose) in rare diseases

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is pleased to announce that it has been awarded a £1.5 million grant from the UK Biomedical Catalyst, a funding programme jointly operated by the UK Medical Research Council (MRC) and Innovate UK. The grant, with additional funding from Heptares, will support a three-year research project aimed at developing first-in-class, selective and orally available small molecule GLP-1 receptor antagonists for the treatment of severe hypoglycaemia (low blood glucose) in rare diseases including congenital hyperinsulinism (CHI). These, often inherited, conditions are characterized by inappropriate and unregulated insulin secretion, causing severe hypoglycaemia, and are associated with poor clinical outcomes including long-term nerve and brain damage.

GLP-1 is a hormone that regulates insulin production in response to blood glucose levels. The activation of its receptor is an important approach for treating diabetes with several products approved. No GLP-1 receptor antagonists are licensed for treating CHI or other related conditions, however experimental and clinical studies with an intravenous peptide antagonist strongly indicate their prospective effectiveness.

The support of the MRC and Innovate UK through this grant will enable Heptares to optimise a series of novel small molecule GLP-1 receptor antagonist compounds identified and developed using its GPCR structure-based development platform. Heptares, in collaboration with the University of Manchester and Great Ormond Street Hospital, London, will then carry out the preclinical development of candidates with the goal of providing novel safe, effective and orally available molecules for clinical studies for CHI with anticipated additional potential in other areas associated with intractable hypoglycaemia; including neonatal hypoglycaemia, hypoglycaemia occurring as a consequence of gastric bypass surgery and insulinoma-associated hypoglycaemia.

Fiona Marshall, Heptares Chief Scientific Officer and co-founder, said: "The ability to precisely drug and regulate the activity of the GLP-1 receptor and thereby regulate and normalize blood glucose levels is an important and validated approach to the treatment of many diseases. We are delighted to receive this grant from the Biomedical Catalyst to fund work that combines the expertise in structure-based drug design at Heptares and the disease expertise of our academic partners to identify new oral treatments for these diseases."

The Biomedical Catalyst is a funding programme jointly operated by the UK Medical Research Council and Innovate UK (formerly the Technology Strategy Board - TSB) providing responsive and effective support for the best translational life science opportunities arising in the UK. Grants are available to UK academics and small and medium enterprises (SMEs) seeking to move their research more quickly from discovery to commercialisation.

About Heptares Therapeutics

Heptares creates transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of drug receptors linked to a wide range of human diseases. Our proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs. Using this approach, we have built an exciting pipeline of new medicines with the potential to transform the treatment of Alzheimer's disease, ADHD, diabetes, schizophrenia, migraine, and other diseases. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR is a registered trademark in the EU and Japan.

About Innovate UK

Innovate UK is the new name for the Technology Strategy Board - we're the UK's innovation agency, accelerating economic growth. We know that taking a new idea to market is a challenge. We fund, support and connect innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth. For further information visit our website at https://www.gov.uk/innovate-uk

Catalysts are run jointly by Innovate UK and the Research Councils. A Catalyst is a form of research and development funding which focuses on a specific priority area and aims to help take projects from research to as close to commercial viability as possible. The Catalyst model supports projects in priority areas where the UK research base has a leading position and where there is clear commercial potential. Current Catalysts include: Biomedical Catalyst, Agri-tech Catalyst and the Industrial Biotechnology Catalyst.

For more details please visit: https://www.gov.uk/innovation-get-details-about-innovate-uk-funding-competitions#catalysts

SOURCE Heptares Therapeutics